Date:11/24/2008

ock will only be made pursuant to the tender offer statement (including the offer to purchase, the letter of transmittal and other offer documents), which was initially filed with the SEC on September 12, 2008 and will be amended to reflect the terms of King's amended offer pursuant to the terms of the merger agreement. The amended offer isscheduled to expire at 5:00 p.m., New York Citytime, on Friday, December 19, 2008, unless extended. If the amended offer is extended, King will notify the depositary for the offer and issue a press release announcing the extension on or before 9:00 a.m., New York City time, on the first business day following the date the offer was scheduled to expire.

Investors and security holders are urged to read the tender offer statement (including the offer to purchase, the letter of transmittal and other offer documents) and any amendments or supplements thereto and any other documents relating to the tender offer that are filed with the SEC carefully and in their entirety because they contain important information. Investors and security holders can obtain free copies of any such documents filed with the SEC by King at www.kingpharm.com and through the web site maintained by the SEC at www.sec.gov. Free copies of any such documents (when available) can also be obtained by directing a request to King's information agent, Innisfree M&A Incorporated, at (877) 687-1875.

In connection with the tender offer by King, Alpharma has filed with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9, which Alpharma will be amending pursuant to the terms of its merger agreement with King. Alpharma stockholders should read carefully the Solicitation/Recommendation Statement on Schedule 14D-9 (including any amendments or supplements thereto)
'/>"/>

SOURCE King Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the Presidents Council on Physical Fitness and Sports, to Board of Directors
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
4. Keryx Biopharmaceuticals Receives Nasdaq Notification
5. Purdue Pharma L.P. Announces a Global Strategic Alliance With Infinity Pharmaceuticals to Advance Discovery and Development Programs in Oncology and Neuropathic Pain
6. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
7. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
8. MiddleBrook Pharmaceuticals Reports Third Quarter 2008 Financial Results
9. MAP Pharmaceuticals Reports Third Quarter of 2008 Financial Results
10. Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit
11. Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts